Expression Levels of Serum Hepcidin, IL-6 and TNF-α and Clinical Significance in Malignant Tumor Patients with Anemia of Chronic Disease
Department of hematology and oncology, Heilongjiang Province hospital, Harbin, Heilongjiang Province, 150036
Cancer Genetics and Epigenetics, 2019, Vol. 7, No. 3 doi: 10.5376/cge.2019.09.0003
Received: 28 Apr., 2019 Accepted: 12 Jun., 2019 Published: 05 Jul., 2019
© 2019 BioPublisher Publishing Platform
This is an open access article published under the terms of the Creative Commons Attribution License
, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
Preferred citation for this article:
Wang L.R., Liu M.L, Zhao J., Wang W.X., and Wang Y.H., 2019, Expression Levels of Serum Hepcidin, IL-6 and TNF-α and Clinical Significance in Malignant Tumor Patients with Anemia of Chronic Disease, 7(3): 19-23 (doi: 10.5376/cge.2019.09.0003)
To explore the effect and possible mechanism of serum hepcidin on malignant tumor patients combined with anemia of chronic disease (ACD). ELISA method was used to measure the concentrations of serum hepcidin, interleukine-6 (IL-6), and tumor necrosis factor α (TNF-α) in 40 malignant tumor patients with ACD. Meanwhile, the concentrations of serum hepcidin, IL-6, and TNF-α in 20 malignant tumor patients without ACD were measured. The differences in above indices between the two groups were compared. Meanwhile, the correlations of hemoglobin (Hb) value with hepcidin, IL-6, and TNF-α in the anemia group were analyzed, and the correlations of hepcidin with IL-6 and TNF-α were analyzed. The serum hepcidin, IL-6 and TNF-α levels in the patients from the anemia group were higher than those in the non-anemia group, which were 49.48±18.38 ng/mL vs. 10.36±5.28 ng/mL, 11.79±4.11 pg/mL vs. 5.46±2.37 pg/mL, and 10.73±3.94 pg/mL vs. 6.48±3.26 pg/mL, respectively(P＜0.05). Besides, Hb value in the patients from the anemia group had negative correlations with serum hepcidin and IL-6 (r values were -0.739 and -0.379, and P＜0.05), but had no correlation with TNF-α (r=-0.213, P>0.05). The serum hepcidin in the patients from the anemia group had a positive correlation with IL-6 (r=0.377, P＜0.05), but had no correlation with TNF-α (r=0.268, P>0.05). Conclusion: Hepcidin plays a critical role in the ACD onset of malignant tumor, and may happen mainly under the participation of IL-6.
Malignant tumor; Anemia of chronic disease; Hepcidin; interleukine-6; Tumor necrosis factor α
Cancer Genetics and Epigenetics
• Volume 7